Najla Al Ali

The role of hypomethylating agents and venetoclax combination in higher risk myelodysplastic syndromes

Rami S. Komrokji, Najla Al Ali, Zena Komrokji, Zhuoer Xie et autres

us (code pays fourni par la source)

Elevated serum erythropoietin level is associated with unique clinical and genomic features, response to treatment, and outcomes in lower-risk myelodysplastic syndromes

Zena Komrokji, Najla Al Ali, Zhuoer Xie, Onyee Chan et autres

us (code pays fourni par la source)

Outcomes of hypomethylating agent (HMA)-based therapy in patients with myelodysplastic syndrome with fibrosis

Abigail Huetteman, Najla Al Ali, David A. Sallman, Eric Padron et autres

us (code pays fourni par la source)

ETNK1 mutations define a distinct subset of myeloid neoplasms with unique cytogenetic and molecular features

Steven Tessier, Najla Al Ali, Michael Trinh, Andrew M. Brunner et autres

us, it (code pays fourni par la source)

Defining evolutionary trajectories in myelodysplastic syndromes and integrating them into prognostic models to improve risk stratification: The progevo machine learning approach

Ivan Civettini, Federica Malighetti, Matteo Villa, Valentina Crippa et autres

it, de, fr, es, us (code pays fourni par la source)

A multicenter real-world study on response and survival in older patients with acute myeloid leukemia treated with intensive chemotherapy versus VEN/HMA by 2022 and 2024 ELN risk stratifications: An analysis from the MARROW consortium

Nilesh Kapoor, Deedra Nicolet, Krzysztof Mrózek, Najla Al Ali et autres

us, mx (code pays fourni par la source)

Oral azacitidine maintenance improved survival for t-AML or AML-MR patients in first remission after CPX-351 and not eligible to HSCT

Caroline Fileni, David M. Swoboda, Alexander Coltoff, Najla Al Ali et autres

fr, us, pt, au, de (code pays fourni par la source)

Durability of complete response outperforms complete response rates as a surrogate endpoint for advancing to phase III trials in high-risk myelodysplastic syndromes

Julie Braish, Najla Al Ali, Zena Komrokji, Zhuoer Xie et autres

us (code pays fourni par la source)

Machine learning using bayesian networks to predict response in patients with newly diagnosed Acute Myeloid Leukemia

Onyee Chan, Najla Al Ali, Seongseok Yun, David A. Sallman et autres

us (code pays fourni par la source)

Mapping out the impact of MAP kinase in primary myelofibrosis

Samuel Reynolds, Andrew Kuykendall, David A. Sallman, Gary W. Reuther et autres

us (code pays fourni par la source)

POSTER: AML-649 Inferior Outcomes in Black Patients With AML: Impact of Genomics and Clinical Risk Factors

Utsav Joshi, Fatima Tuz Zahra, Pujan Patel, Sumeet Kumar Yadav et autres

us (code pays fourni par la source)

AML-649: Inferior Outcomes in Black Patients With AML: Impact of Genomics and Clinical Risk Factors

Utsav Joshi, Fatima Tuz Zahra, Pujan Patel, Sumeet Kumar Yadav et autres